Cargando…
Roles of NAD(+) in Acute and Chronic Kidney Diseases
Nicotinamide adenine dinucleotide (oxidized form, NAD(+)) is a critical coenzyme, with functions ranging from redox reactions and energy metabolism in mitochondrial respiration and oxidative phosphorylation to being a central player in multiple cellular signaling pathways, organ resilience, health,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820289/ https://www.ncbi.nlm.nih.gov/pubmed/36613582 http://dx.doi.org/10.3390/ijms24010137 |
_version_ | 1784865430998876160 |
---|---|
author | Morevati, Marya Fang, Evandro Fei Mace, Maria L. Kanbay, Mehmet Gravesen, Eva Nordholm, Anders Egstrand, Søren Hornum, Mads |
author_facet | Morevati, Marya Fang, Evandro Fei Mace, Maria L. Kanbay, Mehmet Gravesen, Eva Nordholm, Anders Egstrand, Søren Hornum, Mads |
author_sort | Morevati, Marya |
collection | PubMed |
description | Nicotinamide adenine dinucleotide (oxidized form, NAD(+)) is a critical coenzyme, with functions ranging from redox reactions and energy metabolism in mitochondrial respiration and oxidative phosphorylation to being a central player in multiple cellular signaling pathways, organ resilience, health, and longevity. Many of its cellular functions are executed via serving as a co-substrate for sirtuins (SIRTs), poly (ADP-ribose) polymerases (PARPs), and CD38. Kidney damage and diseases are common in the general population, especially in elderly persons and diabetic patients. While NAD(+) is reduced in acute kidney injury (AKI) and chronic kidney disease (CKD), mounting evidence indicates that NAD(+) augmentation is beneficial to AKI, although conflicting results exist for cases of CKD. Here, we review recent progress in the field of NAD(+), mainly focusing on compromised NAD(+) levels in AKI and its effect on essential cellular pathways, such as mitochondrial dysfunction, compromised autophagy, and low expression of the aging biomarker αKlotho (Klotho) in the kidney. We also review the compromised NAD(+) levels in renal fibrosis and senescence cells in the case of CKD. As there is an urgent need for more effective treatments for patients with injured kidneys, further studies on NAD(+) in relation to AKI/CKD may shed light on novel therapeutics. |
format | Online Article Text |
id | pubmed-9820289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98202892023-01-07 Roles of NAD(+) in Acute and Chronic Kidney Diseases Morevati, Marya Fang, Evandro Fei Mace, Maria L. Kanbay, Mehmet Gravesen, Eva Nordholm, Anders Egstrand, Søren Hornum, Mads Int J Mol Sci Review Nicotinamide adenine dinucleotide (oxidized form, NAD(+)) is a critical coenzyme, with functions ranging from redox reactions and energy metabolism in mitochondrial respiration and oxidative phosphorylation to being a central player in multiple cellular signaling pathways, organ resilience, health, and longevity. Many of its cellular functions are executed via serving as a co-substrate for sirtuins (SIRTs), poly (ADP-ribose) polymerases (PARPs), and CD38. Kidney damage and diseases are common in the general population, especially in elderly persons and diabetic patients. While NAD(+) is reduced in acute kidney injury (AKI) and chronic kidney disease (CKD), mounting evidence indicates that NAD(+) augmentation is beneficial to AKI, although conflicting results exist for cases of CKD. Here, we review recent progress in the field of NAD(+), mainly focusing on compromised NAD(+) levels in AKI and its effect on essential cellular pathways, such as mitochondrial dysfunction, compromised autophagy, and low expression of the aging biomarker αKlotho (Klotho) in the kidney. We also review the compromised NAD(+) levels in renal fibrosis and senescence cells in the case of CKD. As there is an urgent need for more effective treatments for patients with injured kidneys, further studies on NAD(+) in relation to AKI/CKD may shed light on novel therapeutics. MDPI 2022-12-21 /pmc/articles/PMC9820289/ /pubmed/36613582 http://dx.doi.org/10.3390/ijms24010137 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Morevati, Marya Fang, Evandro Fei Mace, Maria L. Kanbay, Mehmet Gravesen, Eva Nordholm, Anders Egstrand, Søren Hornum, Mads Roles of NAD(+) in Acute and Chronic Kidney Diseases |
title | Roles of NAD(+) in Acute and Chronic Kidney Diseases |
title_full | Roles of NAD(+) in Acute and Chronic Kidney Diseases |
title_fullStr | Roles of NAD(+) in Acute and Chronic Kidney Diseases |
title_full_unstemmed | Roles of NAD(+) in Acute and Chronic Kidney Diseases |
title_short | Roles of NAD(+) in Acute and Chronic Kidney Diseases |
title_sort | roles of nad(+) in acute and chronic kidney diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820289/ https://www.ncbi.nlm.nih.gov/pubmed/36613582 http://dx.doi.org/10.3390/ijms24010137 |
work_keys_str_mv | AT morevatimarya rolesofnadinacuteandchronickidneydiseases AT fangevandrofei rolesofnadinacuteandchronickidneydiseases AT macemarial rolesofnadinacuteandchronickidneydiseases AT kanbaymehmet rolesofnadinacuteandchronickidneydiseases AT graveseneva rolesofnadinacuteandchronickidneydiseases AT nordholmanders rolesofnadinacuteandchronickidneydiseases AT egstrandsøren rolesofnadinacuteandchronickidneydiseases AT hornummads rolesofnadinacuteandchronickidneydiseases |